Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the News & Events page on Lexeo’s website. A replay will be archived on the investor section of Lexeo’s website following the event.
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LXEO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Lexeo Therapeutics: Behind The Rebound [Seeking Alpha]Seeking Alpha
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.MarketBeat
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- 11/20/25 - Form 4
- LXEO's page on the SEC website